FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine. Described are transdermal therapeutic systems (TTSs), which contain memantine, an NMDA-receptor antagonist or its physiologically compatible salt as a biologically active substance.
EFFECT: transdermal therapeutic systems can be produced and used for treating central nervous system diseases and can administer memantine for a longer period of time, eg at least for 24 h, and pharmacologically effective plasma memantine concentrations can be maintained over this period of time.
15 cl, 4 tbl, 3 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERMOFUSIBLE TTS FOR APPLYING ROTIGOTIN | 2003 |
|
RU2304434C2 |
| TRANSDERMAL THERAPEUTIC SYSTEM | 2006 |
|
RU2450805C2 |
| TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE | 2019 |
|
RU2798017C2 |
| TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING ACTIVE SUBSTANCE BUPRENORPHINE | 2007 |
|
RU2484822C2 |
| BREAKING DISPOSAL OF MEDICINAL ACTIVE INGREDIENTS IN TRANSDERMAL THERAPEUTIC SYSTEMS | 2010 |
|
RU2563131C2 |
| REPLACED TRANSDERMAL OF ADMINISTRATION OF PHENTANYL | 2008 |
|
RU2499583C2 |
| TRANSDERMAL MEMANTINE DELIVERY SYSTEMS | 2017 |
|
RU2764764C2 |
| TRANSDERMAL THERAPEUTIC SYSTEM HAVING NICOTINE AS ACTIVE SUBSTANCE | 2002 |
|
RU2302856C2 |
| TRANSDERMAL PLASTER FOR FENTANYL INTRODUCTION | 2007 |
|
RU2351318C2 |
| TRANSDERMAL PATCH FOR ADMINISTERING FENTANYL | 2002 |
|
RU2708563C2 |
